Skip to content

Clinical trials

Phase 2 Breast Neoplasms, Male trials in the United States

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Breast Neoplasms, Male Phase: Phase 2 Country / region: United States Clear all

88 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20005
20013
20025
20033
20048
200515
20062
200710
20087
20096
20105
20113
20121
20133
20171
20182
20191
20231

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed63
Terminated14
Unknown status5
Active, not recruiting3
Withdrawn2
Recruiting1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
National Cancer Institute (NCI)23
Alliance for Clinical Trials in Oncology10
University of Washington4
Case Comprehensive Cancer Center3
City of Hope Medical Center3
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins3
H. Lee Moffitt Cancer Center and Research Institute2
Memorial Sloan Kettering Cancer Center2
National Institutes of Health Clinical Center (CC)2
Northwestern University2

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Breast Neoplasms, Male88
Breast Neoplasms85
Triple Negative Breast Neoplasms7
Neoplasm Metastasis5
Brain Neoplasms4
Carcinoma, Ductal, Breast4
Inflammatory Breast Neoplasms4
Carcinoma, Lobular3
Carcinoma, Intraductal, Noninfiltrating2
Cardiotoxicity2

Trials

Showing 1 to 25 of 88. Each trial links to its page on Pharma Observatory.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.